These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902 [TBL] [Abstract][Full Text] [Related]
6. [Management of prolactinomas during pregnancy]. Chen W; Bian X; Gai M; Zhang Y Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):335-7. PubMed ID: 12126566 [TBL] [Abstract][Full Text] [Related]
7. Management of prolactinomas during pregnancy. Witek P; Zieliński G Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103 [TBL] [Abstract][Full Text] [Related]
8. [The treatment of prolactinomas during pregnancy and the lactation period]. Rau H; Badenhoop K; Usadel KH Dtsch Med Wochenschr; 1996 Jan; 121(1-2):28-32. PubMed ID: 8565801 [No Abstract] [Full Text] [Related]
9. 2012 update in the treatment of prolactinomas. Maiter D; Primeau V Ann Endocrinol (Paris); 2012 Apr; 73(2):90-8. PubMed ID: 22503806 [TBL] [Abstract][Full Text] [Related]
10. Hyperprolactinaemia. Prabhakar VK; Davis JR Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620 [TBL] [Abstract][Full Text] [Related]
11. Update in prolactinomas. Kars M; Dekkers OM; Pereira AM; Romijn JA Neth J Med; 2010 Mar; 68(3):104-12. PubMed ID: 20308704 [TBL] [Abstract][Full Text] [Related]
12. The management of hyperprolactinaemia. Jones TH Br J Hosp Med; 1995 Apr 19-May 2; 53(8):374-8. PubMed ID: 7599897 [TBL] [Abstract][Full Text] [Related]
13. Prolactinomas and pregnancy. Molitch ME Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542 [No Abstract] [Full Text] [Related]
14. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Casanueva FF; Molitch ME; Schlechte JA; Abs R; Bonert V; Bronstein MD; Brue T; Cappabianca P; Colao A; Fahlbusch R; Fideleff H; Hadani M; Kelly P; Kleinberg D; Laws E; Marek J; Scanlon M; Sobrinho LG; Wass JA; Giustina A Clin Endocrinol (Oxf); 2006 Aug; 65(2):265-73. PubMed ID: 16886971 [TBL] [Abstract][Full Text] [Related]
15. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099 [TBL] [Abstract][Full Text] [Related]
16. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia. Furtado SV; Saikiran NA; Ghosal N; Hegde AS Pediatr Neurol; 2010 Jan; 42(1):72-4. PubMed ID: 20004869 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of prolactinomas. Gillam MP; Molitch ME; Lombardi G; Colao A Endocr Rev; 2006 Aug; 27(5):485-534. PubMed ID: 16705142 [TBL] [Abstract][Full Text] [Related]
18. [Reversible blindness caused by an invasive prolactinoma]. Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749 [TBL] [Abstract][Full Text] [Related]
20. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Chanson P; Maiter D Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]